IRADIMED CORP

For the period ended Dec 31, 2025. Filed Mar 6, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 6, 2026

IRMD$86.94+0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Operations

(in thousands, except per share data)

· · · · · · · · ·
· · · · · Year Ended
· · · · · December 31,
	2025	2024
Revenue	$83,814	$73,242
Cost of revenue	19,490	16,892
Gross profit	64,324	56,350
Operating expenses:
General and administrative	17,782	15,937
Sales and marketing	17,420	15,616
Research and development	2,975	2,832
Total operating expenses	38,177	34,385
Income from operations	26,147	21,965
Other income, net	2,214	2,310
Income before provision for income taxes	28,361	24,275
Provision for income tax expense	5,881	5,041
Net income	$22,480	$19,234
Net income per share:
Basic	$1.77	$1.52
Diluted	$1.75	$1.50
Weighted average shares outstanding:
Basic	12,722	12,670
Diluted	12,854	12,784

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.